Published in Women's Health Weekly, September 15th, 2005
"To determine the efficacy and safety of capecitabine in women with inoperable, recurrent, or metastatic squamous cell cervical cancer," researchers in the United States conducted a "phase II IRB approved trial where capecitabine was given at a dosage of 2000 mg/m2/day orally in a divided dose daily for 14 days followed by a 7-day rest period. A standard dose modification scheme was used with one allowed dose reduction or dose escalation."
"National Cancer Institute criteria for progression, response, and toxicity were utilized," wrote A.D. Jenkins and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly